Lomitapide

Lomitapide , sold under the brand name Juxtapid in the US and Lojuxta in the EU, is a medication used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals.^[3] It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.^[4][5]

Lomitapide

Clinical data
Trade names	Juxtapid (US), Lojuxta (EU)
Other names	AEGR-773, BMS-201038
License data	EU EMA: by INN US DailyMed: Lomitapide US FDA: Lomitapide
Routes of administration	By mouth
ATC code	C10AX12 (WHO)
Legal status
Legal status	US: ℞-only[1] EU: Rx-only[2]
Identifiers
IUPAC name N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9H-fluoren-9-carboxamide
CAS Number	182431-12-5 Y mesylate: 202914-84-9
PubChem CID	9853053 mesylate: 11274333
IUPHAR/BPS	7439
DrugBank	DB08827 Y mesylate: DBSALT000110
ChemSpider	8028764 N mesylate: 9449335
UNII	82KUB0583F mesylate: X4S83CP54E
KEGG	D09637 Y mesylate: D09638
ChEBI	CHEBI:72297 N mesylate: CHEBI:72299
ChEMBL	ChEMBL354541 mesylate: ChEMBL2105662
CompTox Dashboard (EPA)	DTXSID50171294
Chemical and physical data
Formula	C39H37F6N3O2
Molar mass	693.734 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c5ccc(cc5)-c1ccccc1C(=O)NC4CCN(CC4)CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c6ccccc26
InChI InChI=1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49) N Key:MBBCVAKAJPKAKM-UHFFFAOYSA-N N
NY (what is this?)  (verify)

The US Food and Drug Administration (FDA) approved lomitapide in December 2012, as an orphan drug to reduce LDL cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in people with homozygous familial hypercholesterolemia (HoFH).^[6]

In July 2013, the European Commission approved lomitapide as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adults with HoFH.^[2]